Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 5/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | NMT1 | P30419 | 3/20 | 0.39 |
| ▸ | TERT | O14746 | 2/20 | 0.37 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349292 | 0.76 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL4810452 | 0.72 | HSD11B1 (0.61) | HSD11B1FNTAFNTBCNR1 | |
| SCHEMBL4759012 | 0.72 | DRD2 (0.46) | HSD11B1FNTAFNTBCNR1MC4R | |
| SCHEMBL4007689 | 0.68 | PDE4B (0.49) | — | |
| SCHEMBL14498553 | 0.68 | PDE4B (0.49) | — | |
| SCHEMBL3681546 | 0.68 | TBXA2R (0.41) | TBXA2RHSD11B1HTR2AHTR2CHTR2B | |
| SCHEMBL13106518 | 0.68 | EPHX2 (0.50) | HSD11B1 | |
| SCHEMBL4704307 | 0.67 | HSD11B1 (0.56) | HSD11B1FNTAFNTBCNR1 | |
| SCHEMBL6079044 | 0.67 | MEN1 (0.47) | FNTAFNTBHTR2AHTR2CHTR2B | |
| SCHEMBL27686329 | 0.66 | HSD11B1 (0.51) | HSD11B1FNTAFNTBCNR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758582-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| CN-1988908-A | Amido compounds and their use as pharmaceuticals | INCYTE SAN DIEGO INC (US) | 2007-06-27 | — | — | CN | disclosed |
| EP-1758582-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2006002349-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | TBXA2R 264/4885HSD11B1 1/4885NMT1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.